Media stories about Array Biopharma (NASDAQ:ARRY) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Array Biopharma earned a news sentiment score of 0.14 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 44.8943669789636 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment’s analysis:
- PFS Rises with BRAF-MEK Combo in Melanoma (medpagetoday.com)
- Brokerages Expect Array Biopharma Inc (ARRY) Will Announce Quarterly Sales of $32.07 Million (americanbankingnews.com)
- Array Biopharma Inc (ARRY) Insider Victor Sandor Sells 8,689 Shares (americanbankingnews.com)
- ValuEngine Upgrades Array Biopharma (ARRY) to “Buy” (americanbankingnews.com)
- Is There An Opportunity With Array BioPharma Inc’s (NASDAQ:ARRY) 32% Undervaluation? (finance.yahoo.com)
ARRY has been the topic of a number of recent analyst reports. Leerink Swann upgraded Array Biopharma from a “market perform” rating to an “outperform” rating in a report on Monday, January 22nd. BidaskClub lowered Array Biopharma from a “hold” rating to a “sell” rating in a report on Wednesday, March 21st. SunTrust Banks reiterated a “buy” rating and set a $20.00 price target on shares of Array Biopharma in a report on Tuesday, February 6th. Jefferies Group lifted their price target on Array Biopharma to $13.00 and gave the stock a “buy” rating in a report on Friday, December 22nd. Finally, ValuEngine upgraded Array Biopharma from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Array Biopharma has an average rating of “Buy” and a consensus price target of $17.25.
Array Biopharma (NASDAQ:ARRY) last released its earnings results on Tuesday, February 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.06. Array Biopharma had a negative return on equity of 107.79% and a negative net margin of 98.51%. The business had revenue of $42.21 million during the quarter, compared to the consensus estimate of $26.81 million. During the same period last year, the business posted ($0.14) earnings per share. The business’s revenue for the quarter was down 5.2% on a year-over-year basis. equities research analysts predict that Array Biopharma will post -0.88 EPS for the current fiscal year.
In other Array Biopharma news, Director Lunsen Gil J. Van sold 21,500 shares of the firm’s stock in a transaction on Wednesday, March 21st. The stock was sold at an average price of $16.76, for a total value of $360,340.00. Following the completion of the sale, the director now directly owns 26,297 shares of the company’s stock, valued at $440,737.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Victor Sandor sold 8,689 shares of the firm’s stock in a transaction on Tuesday, April 3rd. The stock was sold at an average price of $15.35, for a total value of $133,376.15. The disclosure for this sale can be found here. Insiders sold 286,705 shares of company stock valued at $4,851,885 over the last three months. Company insiders own 3.18% of the company’s stock.
Array Biopharma Company Profile
Array BioPharma Inc is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. The Company’s programs include approximately three cancer drugs, binimetinib, encorafenib and selumetinib (partnered with AstraZeneca, PLC).
Receive News & Ratings for Array Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Array Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.